title: High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
authors.affiliation: Department of Neurology, St. Vincent's University Hospital, Dublin, Ireland.
authors.forename: Siew Mei
authors.initials: SM
authors.lastname: Yap
authors.affiliation: Department of Neurology, St. Vincent's University Hospital, Dublin, Ireland.
authors.forename: Christopher
authors.initials: C
authors.lastname: McGuigan
mesh_terms: D000328:Adult; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007577:JC Virus / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000097:blood* / Q000000981:diagnostic imaging* / Q000209:etiology; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab / Q000009:adverse effects*; D017410:Practice Guidelines as Topic
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab